The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: An analysis of data from a large midwestern state

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 498-503

  Berkowitz, Rachel L ^a   Patel, Urvashi ^c   Ni, Quanhong ^c   Parks, Joseph J ^d   Docherty, John P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Care Management Technologies Inc   (United States)

^d MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; ICD-9; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; UNITED STATES;

EID: 84860566325     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06497     Document Type: Article

References (28)

1. Drake R, Skinner J, Goldman HH. What explains the diffusion of treatments for mental illness? Am J Psychiatry. 2008;165(11):1385-1392. doi:10.176/api.ajp.208.0803034 PubMed
2. Ornstein S, Nietert PJ, Jenkins RG, et al. Improving the translation of research into primary care practice: results of a national quality improvement demonstration project. Jt Comm J Qual Patient Saf. 2008;34(7):379-390. PubMed
3. Harpaz-Rotem I, Rosenheck RA. Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs. Arch Gen Psychiatry. 2009;66(4):417-421. doi:10.101/archgenpsychiatry.208.536 PubMed
4. Tee A, Calzavacca P, Licari E, et al. Bench-to-bedside review: the MET syndrome - the challenges of researching and adopting medical emergency teams. Crit Care. 2008;12(1):205. doi:10.186/c619 PubMed
5. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362(9391):1225-1230. doi:10.1016/S0140-6736(03)14546-1 PubMed (Pubitemid 37255352)
6. Fluckiger SL. Industry's challenge to academia: changing the bench to bedside paradigm. Exp Biol Med (Maywood). 2006;231(7):1257-1261. PubMed (Pubitemid 44050471)
7. Simpson DD. A conceptual framework for transferring research to practice. J Subst Abuse Treat. 2002;22(4):171-182. doi:10.1016/S0740-5472(02)0231-3 PubMed (Pubitemid 34606036)
8. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? a framework for improvement. JAMA. 1999;282(15):1458-1465. doi:10.101/jama.282.15.1458 PubMed (Pubitemid 29493800)
9. Lieberman JA, Stroup TS, McEvoy JP, et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
10. Rosenheck RA, Leslie DL, Sindelar J, et al CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-2089. doi:10.176/api.ajp.163.12.2080 PubMed (Pubitemid 46114227)
11. Kraemer HC, Glick ID, Klein DF. Clinical trials design lessons from the CATIE study. Am J Psychiatry. 2009;166(11):1222-1228. doi:10.176/api.ajp.209. 08121809 PubMed
12. McEvoy JP, Lieberman JA, Stroup TS, et al CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610. doi:10.176/api.ajp.163.4.60 PubMed (Pubitemid 44464569)
13. Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull. 2009;35(5):931-936. doi:10.1093/schbul/sbn019 PubMed
14. Duckworth K, Fitzpatrick MJ. NAMI perspective on CATIE: policy and research implications. Psychiatr Serv. 2008;59(5):537-539. doi:10.176/api.ps.59. 5.537 PubMed
15. Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv. 2008;59(5):500-506. doi:10.176/api.ps.59.5.50 PubMed
16. Petersen TJ, Huffman JC, Weiss AP, et al. Reach of benchmark psychiatric trial results to community-based providers: a case study of CATIE. J Clin Psychiatry. 2008;69(7):1081-1086. doi:10.408/JCP.v69n0706 PubMed (Pubitemid 352031590)
17. Citrome L, Jaffe A, Martello D, et al. Did CATIE influence antipsychotic use? Psychiatr Serv. 2008;59(5):476. doi:10.176/api.ps.59.5.476 PubMed
18. Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr. 2003;8(suppl 2):19-22. PubMed (Pubitemid 38405537)
19. Alméras N, Després JP, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004;65(4):557-564. doi:10.408/JCP.v65n0417 PubMed
20. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18):47-56. PubMed
21. Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930-1941. doi:10.1016/j.clinthera.205.12.05 PubMed (Pubitemid 43293215)
22. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006;186(4):572-578. doi:10.107/s0213-06-0384-5 PubMed
23. Berenson A. Disparity emerges in Lilly data on schizophrenia drug. The New York Times; Nov 21, 2006
24. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151-156. doi:10.1097/YCO.0b013e3282f53132 PubMed (Pubitemid 351339869)
25. Parks JJ, Radke AQ, Tandon R. Impact of the CATIE findings on state mental health policy. Psychiatr Serv. 2008;59(5):534-536. doi:10.176/api.ps.59. 5.534 PubMed
26. Tandon R, Belmaker RH, Gattaz WF, et al Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38. doi:10.1016/j.schres.207.1.03 PubMed
27. Rosenheck RA, Leslie DL, Busch S, et al. Rethinking antipsychotic formulary policy. Schizophr Bull. 2008;34(2):375-380. doi:10.1093/schbul/sbm089 PubMed (Pubitemid 351323323)
28. Conway PH, Clancy C. Charting a path from comparative effectiveness funding to improved patient-centered health care. JAMA. 2010;303(10):985-986. doi:10.101/jama.2010.259 PubMed